Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Long-Term Investments (2018 - 2025)

Catalyst Pharmaceuticals' Long-Term Investments history spans 5 years, with the latest figure at $22.5 million for Q4 2025.

  • For Q4 2025, Long-Term Investments rose 4.51% year-over-year to $22.5 million; the TTM value through Dec 2025 reached $22.5 million, up 4.51%, while the annual FY2025 figure was $22.5 million, 4.51% up from the prior year.
  • Long-Term Investments reached $22.5 million in Q4 2025 per CPRX's latest filing, up from $19.2 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $24.2 million in Q1 2025 to a low of $12.9 million in Q3 2023.
  • Average Long-Term Investments over 3 years is $18.1 million, with a median of $17.8 million recorded in 2023.
  • The largest YoY upside for Long-Term Investments was 62.47% in 2025 against a maximum downside of 4.51% in 2025.
  • A 3-year view of Long-Term Investments shows it stood at $16.5 million in 2023, then soared by 30.78% to $21.6 million in 2024, then grew by 4.51% to $22.5 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Long-Term Investments are $22.5 million (Q4 2025), $19.2 million (Q3 2025), and $21.3 million (Q2 2025).